Case Reports in Oncology最新文献

{"title":"Long-Term Survival after Stereotactic Radiotherapy Combined with Immunotherapy in a Patient with Recurrent Oral Cancer.","authors":"Paweł Polanowski, Marlena Howorus, Aleksandra Nasiek, Anna Kozub, Agnieszka Pietruszka, Katarzyna Drosik-Rutowicz, Katarzyna Polanowska, Krzysztof Składowski","doi":"10.1159/000542321","DOIUrl":"10.1159/000542321","url":null,"abstract":"<p><strong>Introduction: </strong>Recurrent oral squamous cell carcinoma (SCC) poses significant challenges in treatment, requiring a multifaceted approach for effective management.</p><p><strong>Case presentation: </strong>We present the case of a 68-year-old patient with a history of keratonizing SCC of the mandibular gingiva, treated with surgical resection, adjuvant radiotherapy (RT) to a total dose of 60 Gy in 30 fractions and 6 cycles of concurrent chemotherapy. After 6 years of follow-up, the patient experienced a local late recurrence in clinical stage rT4N0M0 requiring palliative chemotherapy (6 cycles of PF regimen). Due to progression, nivolumab-based immunotherapy was administered. After the 11th cycle of immunotherapy, high-dose re-irradiation (18 Gy in 3 fractions) was applied due to subsequent progression. The addition of stereotactic RT to the immunotherapy allowed nivolumab to be continued until cycle 64, ensuring long-term disease stabilization with acceptable tolerability. Consecutive palliative chemotherapy included paclitaxel and methotrexate.</p><p><strong>Conclusion: </strong>This case highlights the complex management of recurrent oral SCC, emphasizing the role of combining stereotactic RT with nivolumab in prolonging the administration of immunotherapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1366-1373"},"PeriodicalIF":0.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nasopharyngeal Metastasis from Lung Adenocarcinoma: A Case Report and Literature Review.","authors":"Chiara Conti, Sabrina Nucera, Giuseppe Di Grazia, Federica Martorana, Fabio Motta, Paolo Vigneri, Alfio M Di Grazia","doi":"10.1159/000539018","DOIUrl":"10.1159/000539018","url":null,"abstract":"<p><strong>Introduction: </strong>Managing uncommon metastatic sites from different solid tumors is challenging since no available guidelines define the best therapeutic approaches for these rare clinical events. Thus, malignancies giving rise to distant metastases involving infrequent anatomical regions are often associated with a poor prognosis.</p><p><strong>Case presentation: </strong>We present the case of a 75-year-old man who developed uncontrolled epistaxis following the detection of a metachronous nasopharyngeal metastasis from a previous lung adenocarcinoma. The lesion was identified with a computed tomography scan and its origin from the earlier non-small cell lung cancer was confirmed by a biopsy. The patient was successfully treated with radiation therapy and is currently continuing his oncological follow-up. To the best of our knowledge, this is the fifth reported case of a lung malignancy spreading to the nasopharyngeal region.</p><p><strong>Conclusion: </strong>Meticulous patient monitoring and accurate radiological diagnosis followed by histological confirmation are of paramount importance for the management of uncommon metastatic sites. Likewise, a multidisciplinary approach is essential to devise the appropriate treatment strategy for each patient with locoregional interventions, such as radiation therapy, often playing a pivotal role for the management of symptomatic lesions in unusual anatomical sites.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1358-1365"},"PeriodicalIF":0.7,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical Presentation of an Ovarian Yolk Sac Tumor in an 80-Year-Old Woman: A Case Report and Review of the Literature.","authors":"Vanessa Maldonado, María Masvidal, Vanessa Morente Laguna, Jacqueline Cimerman, Salvador Martinez Soriano","doi":"10.1159/000542244","DOIUrl":"10.1159/000542244","url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian yolk sac tumors after the menopause are very rare.</p><p><strong>Case presentation: </strong>We report an atypical case of yolk sac tumor in an octogenarian woman, who presented to the hospital with anasarca, ascites, toxic syndrome, and an abdominal mass. Serum alpha-fetoprotein (AFP) levels were highly increased (246,720 ng/mL), and malignant cells with positive AFP immunohistochemical expression were detected in a diagnostic paracentesis. The definitive diagnosis was established by histopathological examination of the surgical specimen and immunohistochemical detection of positivity for AFP, glypican 3, cytokeratin AE1/AE3, and focal positivity for SALL4 and CK7. Adjuvant chemotherapy was refused by the patient. Postoperative AFP values decreased to normal limits. One year after surgery, she remains in good clinical condition without evidence of tumor recurrence. In a review of the literature, 11 cases of yolk sac tumors in postmenopausal women were collected. The mean age of the patients was 63.4 years (range 58-82 years). Frequent findings were FIGO stage II, cytoreductive surgery, immunohistochemical analyses of a large panel of markers, postoperative chemotherapy, and no tumor recurrence (except in 1 patient who died), although the length of follow-up was relatively short or unclearly stated.</p><p><strong>Conclusion: </strong>The present case report illustrates that yolk sac tumors in very old women may have a favorable clinical course without signs of recurrence even in the absence of radical surgical resection with curative intent and associated adjuvant chemotherapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1342-1350"},"PeriodicalIF":0.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Warm Autoimmune Hemolytic Anemia as First Presentation of Chronic Myeloid Leukemia: A Case Report.","authors":"Ahmad Tawalbeh, Abdulrahman Al-Mashdali, Ahmad Al-Sabbagh, Anil Y Ellahi, Mohamed A Yassin","doi":"10.1159/000542341","DOIUrl":"10.1159/000542341","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome and uncontrolled granulocyte production. While autoimmune hemolytic anemia (AIHA) is commonly associated with lymphoproliferative disorders such as chronic lymphocytic leukemia, its occurrence in CML is rare, with only a few documented cases. Here, we report a case of concurrent chronic-phase CML and AIHA.</p><p><strong>Case presentation: </strong>We present a 34-year-old female diagnosed with warm AIHA as the first presentation of CML. Diagnostic workup, including peripheral smear, revealed hemolysis with elevated lactate dehydrogenase and a positive direct antiglobulin test (DAT), along with a positive Philadelphia chromosome, confirming CML. Steroid therapy successfully managed the AIHA, leading to normalization of hemoglobin levels and subsequent tapering and discontinuation of steroids.</p><p><strong>Conclusion: </strong>While AIHA is a rare cause of anemia in CML, it should be considered during anemia evaluation, particularly in cases of CML relapse.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1351-1357"},"PeriodicalIF":0.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic/Sacral Chondrosarcoma with Brain Metastasis: A Case Report.","authors":"Catalina Herrán-Fonseca, Jorge Luis Vargas-Rojas, Ramón Alejandro Andreu-Atuesta, Sergio Andrés Salgado-Rueda","doi":"10.1159/000541620","DOIUrl":"https://doi.org/10.1159/000541620","url":null,"abstract":"<p><strong>Introduction: </strong>Chondrosarcomas are cartilaginous tumors primarily known for metastasizing to the lungs and bones. Their spread to the central nervous system is infrequent.</p><p><strong>Case presentation: </strong>We present the case of a 32-year-old woman with a history of pelvic/sacral grade III chondrosarcoma (L4-S2; T3N0MX; Ki67; 30%), who underwent surgical resection and radiotherapy. She presented to the emergency department with a 2-day history of thunderclap headache accompanied by fever and chills. Computed axial tomography (CT) scan revealed a left occipital intraparenchymal lesion, subsequently confirmed as suggestive of a neoplastic lesion on magnetic resonance imaging. Ten days after admission, she experienced a two-minute generalized tonic-clonic seizure episode, followed by postictal stupor, tachycardia, hypertension, and anisochoric pupils. A follow-up CT scan demonstrated progression of the metastatic lesion, with evidence of uncal and foraminal herniation. Compression of the cardiorespiratory center at the bulbar level led to her death.</p><p><strong>Conclusion: </strong>This case report offers insight into the clinical presentation, behavior, and prognosis of a metastatic brain lesion derived from grade III chondrosarcoma. It is important to correlate the patient's medical history with imaging findings to achieve an accurate diagnosis, especially in situations where biopsy may not be feasible.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1335-1341"},"PeriodicalIF":0.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osimertinib for Uncommon Endothelial Growth Factor Receptor-Mutant Non-Small Cell Lung Carcinoma: A Case Report.","authors":"Niveditha Popuri, Vishnu Nagalapuram, Unaiza Zaman, Raid Aljumaily","doi":"10.1159/000542201","DOIUrl":"10.1159/000542201","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) accounts for 84% of all lung cancers and continues to remain the leading cause of cancer-related mortality worldwide. The advent of gene targeted therapies has changed the landscape of NSCLC management. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) that has activity against exon 19, exon 21 (L858R) mutations. It is also active against T790M mutation which is the most common resistant mechanism to earlier generation TKIs. Activity of osimertinib against rare EGFR mutations is largely unknown. We report the case of a 64-year-old woman with metastatic NSCLC carrying an exceedingly rare deletion-insertion exon 19 EGFR mutation (p.E746_S752delinsV) who demonstrated sustained disease control with osimertinib, achieving a progression-free survival of 26 months.</p><p><strong>Case presentation: </strong>A 64-year-old nonsmoker female presented with back pain for 1 month. Magnetic resonance imaging spine showed pathological fracture secondary to multiple lytic lesions. She underwent FDG PET/CT that showed large left lower lobe mass, bilateral pulmonary nodules, widespread osteolytic lesions. She underwent iliac lytic lesion biopsy that was consistent with adenocarcinoma (TTF1- and CK7-positive). Tumor tissue next-generation sequencing showed EGFR exon 19 mutation (DNA change: c.2237_2255delinsT, amino acid change: p.E746_S752delinsV [Glu 746_Ser752delinsval]). She was started on osimertinib and showed clinical response within 2 weeks of starting therapy. She was able to maintain a response for 26 months since starting treatment.</p><p><strong>Conclusion: </strong>In summary, there are limited prospective data to guide therapy in patients with rare EGFR mutations. Prospective studies are required to evaluate the response to endothelial growth factor receptor-tyrosine kinase inhibitors in patients with rare EGFR mutations in order to ensure patient safety and response to treatment in this patient population.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1329-1334"},"PeriodicalIF":0.7,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rhabdomyolysis Occurred Again after Changing Chemotherapy Regimens in Ovarian Cancer: A Case Report.","authors":"Shaocong Cao, Tao Peng","doi":"10.1159/000542103","DOIUrl":"10.1159/000542103","url":null,"abstract":"<p><strong>Introduction: </strong>The incidence of chemotherapy-induced rhabdomyolysis is rare, but it is a syndrome that may cause death and should be paid attention to clinically.</p><p><strong>Case presentation: </strong>Here, we report a case of rhabdomyolysis in an ovarian cancer patient after chemotherapy. After the symptoms were relieved, the chemotherapy regimen was changed, and rhabdomyolysis occurred again.</p><p><strong>Conclusion: </strong>The occurrence of rhabdomyolysis is mainly caused by certain specific chemotherapy drugs such as gemcitabine and paclitaxel and is not closely related to other factors such as the patient's constitution or genetic factors. And the occurrence of rhabdomyolysis can be caused by conventional doses of drugs rather than high dose. If rhabdomyolysis occurs and is completely relieved, chemotherapy may be considered again depending on the patient's condition and physical condition. However, caution should be exercised in selecting drugs to avoid recurrence of rhabdomyolysis, and the condition should be closely monitored.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1322-1326"},"PeriodicalIF":0.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous Urothelial Carcinoma in the Upper Urinary Tract and Contralateral Renal Cell Carcinoma: A Case Report.","authors":"Keisuke Ishikawa, Masayoshi Nagata, Miki Tomari, Osamu Mito, Hisashi Hirano, Fumitaka Shimizu, Shuji Isotani, Hisamitsu Ide, Shigeo Horie","doi":"10.1159/000542059","DOIUrl":"10.1159/000542059","url":null,"abstract":"<p><strong>Introduction: </strong>Although urological surgeons often diagnose cases of simultaneous double cancers of the urinary tract in our clinical practice, few reports have shown that treatment strategies achieve both anticancer effects and preservation of renal function for simultaneous contralateral renal cell carcinoma and urothelial carcinoma. Although there are many options for the treatment of renal cancer, such as immunotherapy and - drugs, and many surgical procedures, such as laparoscopic surgery and robot-assisted surgery, no treatment strategy has been established for double cancer of the bilateral urinary tracts. We encountered a case in which contralateral renal surgery was performed under a precise preoperative plan; as a result, the introduction of dialysis could be avoided, and the anticancer effect could be maintained.</p><p><strong>Case presentation: </strong>A 73-year-old man was diagnosed with contralateral left renal cell carcinoma and right ureteral cancer. Initially, the patient underwent laparoscopic radical nephroureterectomy for right ureteral urothelial carcinoma. Subsequently, robot-assisted laparoscopic partial nephrectomy for left renal cell carcinoma was performed after treatment with the molecular-targeted agent, pazopanib. Even after partial nephrectomy, renal function was maintained, and dialysis was avoided.</p><p><strong>Conclusion: </strong>In cases of simultaneous renal cell carcinoma and contralateral ureteral cancer, it is possible to preserve both anticancer effects and renal function using careful treatment strategies.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1316-1321"},"PeriodicalIF":0.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Screening and Identification of an Asymptomatic Pheochromocytoma in a Child with Von Hippel-Lindau: A Case Report.","authors":"Kristine Schmeling, Jennifer Schuh, Dave Lal, Kerri Becktell","doi":"10.1159/000541527","DOIUrl":"10.1159/000541527","url":null,"abstract":"<p><strong>Introduction: </strong>Von Hippel-Lindau (VHL) is a diagnosis that leads to increased risk of tumor development over the course of a patient's lifetime. Patients with VHL undergo screening for multiple tumor types, including pheochromocytomas (PCCs). There is variability among the different international guidelines regarding the age to begin PCC screening, with most suggesting 5 years for screening initiation.</p><p><strong>Case presentation: </strong>Our patient is a 4-year-old female who underwent screening for PCC at the time of her VHL diagnosis while asymptomatic that identified a unilateral PCC. This was amendable to treatment with laparoscopic partial adrenalectomy.</p><p><strong>Conclusion: </strong>This is the first report of an asymptomatic PCC being identified in a patient under the age of 5. With early identification, this was treated surgically before it caused systemic symptoms with preservation of normal adrenal gland tissue. This supports adhering to the pediatric specific guidelines which recommend earlier initiation of PCC screening in pediatric patients with VHL.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1309-1315"},"PeriodicalIF":0.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11563656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basosquamous Carcinoma Arising from the Vulva: A Case Report.","authors":"Fatma Saadallah, Ayoub Ghazouani, Ines Zemni, Haykel Turki, Houyem Mansouri, Ghada Sahraoui, Tarek Ben Dhiab","doi":"10.1159/000541967","DOIUrl":"https://doi.org/10.1159/000541967","url":null,"abstract":"<p><strong>Introduction: </strong>Basosquamous carcinoma (BSC) of the vulva is an uncommon tumor that primarily consists of basal cell carcinoma with squamous differentiation. Also known as metatypical basal cell carcinoma, BSC is typically classified as a skin cancer and represents only 2% of non-melanoma skin malignancies. This type of carcinoma has a poorer prognosis than basal cell carcinoma due to its increased local aggressiveness and metastatic potential.</p><p><strong>Case presentation: </strong>We present the case of a 59-year-old woman with a 3-year history of a slow-growing and painful vulvar lesion. Clinical examination revealed a 35-mm nodular, ulcerating, and non-pigmented lesion located on the labia majora. A biopsy confirmed the diagnosis of BSC, and staging assessments indicated no evidence of metastasis. The patient underwent partial radical vulvectomy and sentinel lymph node biopsy, with histological analysis revealing distinct features characteristic of BSC, including basaloid cell islands and areas of significant squamous differentiation. The excision margins were tumor-free, and all six lymph nodes examined were negative for metastases. Regular surveillance for 6 months was conducted without signs of recurrence.</p><p><strong>Conclusion: </strong>After reviewing the literature, this case represents the sixth documented instance of vulvar BSC. Compared to basal cell carcinoma, BSC has a poorer prognosis, with a higher potential for recurrences and metastases. While basal cell carcinoma is much more prevalent among vulvar and skin malignancies, recognizing the squamous differentiation component is crucial for ensuring wider margins during surgical excision.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1282-1288"},"PeriodicalIF":0.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}